Fig. 8

AntagomiR-100-5p rescued the suppression of osteogenesis of hBMSCs and angiogenesis of HUVECs caused by NONFH exosomes. A The expression of miR-100-5p in hBMSCs was measured by RT-PCR. B WB was used to detect the expressions of BMPR2, SMAD1/5/9, p-SMAD1/5/9, collagen type 1, OCN, RUNX2, ALP, OPN, and PPARγhBMSCs. C The expression of miR-100-5p in HUVECs was measured by RT-PCR. D WB was used to detect the expression of BMPR2, BMPR2, SMAD1/5/9, p-SMAD1/5/9, FGF2, and VEGFA in HUVECs. E ALP staining of hBMSCs (scale bar = 100 μm). F Alizarin Red S staining of hBMSCs after cultured in ODM for 14 days. G Oil Red staining of hBMSCs (scale bar = 50 μm). H Tube formation assay of HUVECs (scale bar = 200 μm). I Semiquantitative analysis of ALP staining. J Quantitative analysis of ARS staining. K Quantitative analysis of Oil Red O staining. L Quantitative analysis of tube formation. PBS, treatment with PBS; NONFH exosomes, treatment with NONFH exosomes; NONFH exosomes+ NC, treatment with NONFH exosomes and NC; treatment with NONFH exosomes +antagomiR-100-5p, treatment with NONFH exosomes and antagonist of miR-100-5p; NM-CTL, controls for differentiation. *P < 0.05, versus NC group; #P < 0.05, versus agomiR-100-5p group. NS P>0.05, versus PBS group All data were expressed as mean ± SEM